Cancer-associated thrombosis.

Venous thromboembolic events are common in patients with malignancy, producing both morbidity and mortality. Although the underlying mechanisms by which cancer might promote a procoagulant state are multifaceted and incompletely understood, recent translational research has significantly advanced our understanding of the relationship between cancer and thrombosis. The occurrence of a thromboembolic event in a patient with an active malignancy should be regarded as a life-threatening complication, and decisions regarding prevention and treatment are usually complex. Outcomes may be improved by an evidence-based approach to management with consideration of practice guidelines. Copyright 2010 Elsevier Inc. All rights reserved.